Grifols (GRFS) Net Income - Minority (2010 - 2011)
Grifols (GRFS) reported Net Income - Minority of -$3.4 million for Q4 2011, up 82.8% on a YoY basis from -$1.8 million in Q4 2010, and up 82.8% quarter-over-quarter from -$19.5 million in Q4 2010.
Grifols (GRFS) Net Income - Minority (2010 - 2011) Analysis & Trends
Grifols has reported Net Income - Minority for 2 years, with the latest figure at -$3.4 million in Q4 2011.
- For the quarter ending Q4 2011, Net Income - Minority rose 82.8% year-over-year to -$3.4 million; the trailing twelve-month figure through Dec 2011 stood at -$3.4 million (up 82.8% YoY), and the FY2011 full-year result was -$3.4 million, up 82.8% from the prior year.
- Net Income - Minority for Q4 2011 stood at -$3.4 million, up from -$19.5 million in the prior quarter.
- The five-year high for Net Income - Minority was -$3.4 million in Q4 2011, with the low at -$19.5 million in Q4 2010.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income - Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | - |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | - |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | - |
| 10 | Grifols | 6.05 Bn | 5.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2011 | -3.35 Mn |
| Dec 31, 2010 | -19.49 Mn |